TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Alvotech
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Alvotech announced the European launch of Gobivaz® (golimumab), the first-in-market biosimilar to Simponi® globally, commercialized by partner Advanz Pharma. The launch is supported by an NHS England tender award in the United Kingdom, which provides a defined framework for adoption within NHS services for treating immune-mediated inflammatory diseases.

Insights
ALVO   positive

Alvotech achieved a significant milestone as the first company to launch a biosimilar to Simponi globally, secured NHS England tender award supporting market adoption, and demonstrated regulatory approval through comprehensive clinical studies. This represents successful commercialization and market validation.